文献速递肝病

肝脏GPR75通过GNAI2依赖信号加重MASH

Hepatic GPR75 exacerbates MASH through GNAI2-dependent signaling.
PubMed 文献 · Hepatology · 2026-02-03

本研究探讨肝脏GPR75在MASH进展中的作用。健康人肝脏GPR75表达不高,但MASH时蛋白水平显著升高;全肝或肝细胞敲除Gpr75可保护小鼠免受饮食诱导的肝脂肪变,而肝细胞过表达Gpr75则加重饮食诱导的MASH和肝纤维化。肝Gpr75缺失激活GNAI2-cAMP-PKA通路,减少SREBP-1c成熟和新生脂肪生成;VPS35通过回收GPR75至肝细胞膜使其稳定。结论提示抑制GPR75可能成为MASLD/MASH治疗策略。

要点

  • 肝细胞GPR75在MASH中蛋白水平显著升高。
  • 敲除肝Gpr75可减轻饮食诱导的肝脂肪变。
  • 肝细胞过表达Gpr75加重MASH和肝纤维化。

核心结论

  • GPR75是MASLD/MASH的新型调控因子,通过调节肝脏脂肪酸代谢发挥作用。
  • 抑制GPR75可能成为MASLD/MASH的潜在治疗策略。

研究设计与样本

  • 研究论文,包含小鼠饮食诱导MASH模型及全肝或肝细胞特异性Gpr75敲除与过表达实验。

主要发现

  • 健康个体肝脏GPR75表达不高,但MASH时蛋白水平显著增加。
  • 全肝或肝细胞敲除Gpr75可保护小鼠免受饮食诱导的肝脂肪变。
  • 肝细胞特异性过表达Gpr75加重饮食诱导的MASH和肝纤维化。
  • 肝Gpr75缺失激活GNAI2-cAMP-PKA信号,减少SREBP-1c成熟和新生脂肪生成。
  • VPS35通过回收GPR75至肝细胞膜使其稳定,减少MASH进展中的降解。

临床怎么用

  • GPR75及其下游GNAI2-cAMP-PKA-SREBP-1c轴可作为MASLD/MASH药物开发候选靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD), including its more severe form, metabolic dysfunction-associated steatohepatitis (MASH), is increasingly recognized as a critical global health challenge. This study investigates the role of hepatic GPR75 in MASH progression. APPROACH AND RESULTS: Although GPR75 is not abundantly expressed in the liver in healthy individuals, its protein levels significantly increase during MASH. Depletion of Gpr75 in either the whole liver or specifically in hepatocytes protected mice from diet-induced hepatic steatosis, while hepatocyte-specific overexpression of Gpr75 exacerbated diet-induced MASH and liver fibrosis. The deficiency of hepatic Gpr75 activated the GNAI2-cAMP-PKA signaling pathway in the livers of MASLD mice, reducing SREBP-1c maturation and de novo lipogenesis. Mechanistically, VPS35 stabilized GPR75 by recycling it to the hepatocyte membrane, thereby decreasing its degradation during MASH progression. CONCLUSIONS: This study demonstrates that GPR75 serves as a novel regulator of MASLD/MASH by modulating hepatic fatty acid metabolism. These findings suggest that GPR75 suppression may represent a potential therapeutic strategy for MASLD/MASH treatment.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yang X, Yang N, Cheng Z, et al. Hepatic GPR75 exacerbates MASH through GNAI2-dependent signaling. Hepatology. 2026. PMID: 41632920. doi:10.1097/HEP.0000000000001706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。